JAK Inhibitors in Difficult Still’s Disease A small retrospective study suggests that patients with difficult to treat AOSD or sJIA may respond well to JAKi agents - presumable by blocking pro-inflammatory cytokines, notably IL-6 and IFN. https://t.co/cH9wb8bPTX https://t.co/Xm7DUC5okk